LSPN 19: choose your IP strategy wisely, warn IP experts
24-10-2019
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22-10-2019
Novartis and Microsoft to collaborate on AI in medicine
03-10-2019
Anna Yuan (left) and Karen Potter (right)
Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
LSPN 2019, artificial intelligence, patent, AI-related, inventions, Morrison & Foerster, patent filings, medicine, drug, prices, Canada, Patented Medicine
